Renalytix AI (GB:RENX) has released an update.
Renalytix AI, a leader in AI-enabled kidney disease diagnostics, has terminated its formal sale process due to the board’s belief that a near-term offer is unlikely. The company is refocusing on its business plan, which includes cost reductions and a refreshed investment strategy, while continuing to explore options to enhance shareholder value. This decision comes despite the company’s operational progress, including FDA approval for its KidneyIntelX test and a positive Medicare coverage determination.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
